Praxis Precision Medicines, Inc. (PRAX)

NMS – Real vaqt narxi. Valyuta: USD

377.32

+6.64 (1.79%)

Bozor ochiq: Aug 12, 2026, 2:53 PM EDT

370.68

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

11.08.2026

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

07.08.2026

Praxis: Commercial Launch Could Smash Expectations (Video)

Prax is analyzed using a sum-of-parts valuation approach, focusing on its lead asset, Ulixa. Recent updates from the Goldman Sachs presentation highlight key developments ahead of Ulixa's commercial launch. I assess PRAX's strategic positioning and upcoming catalysts tied to Ulixa's market entry.

07.08.2026

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

07.08.2026

Praxis Precision Medicines Q2 Earnings Call Highlights

Praxis Precision Medicines NASDAQ: PRAX said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, or DEEs, as both new drug applications remain under FDA review.

06.08.2026

Stock Picks From Seeking Alpha's July 2026 New Analysts

Seeking Alpha welcomed 33 new analysts in July 2026. This article showcases their top picks and investment strategies. Highlighted companies include SELLAS Life Sciences, Chevron, B2Gold, Amazon, and QXO, each with detailed investment theses. Analysts emphasize asymmetric opportunities, event-driven catalysts, balance sheet strength, market structure, and sector-specific growth or risk factors.

04.08.2026

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on August 3, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 7,318 shares of its common stock to twenty-nine new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

Videolar

No Data

There is no data to display

Press-relizlar

04.08.2026

Praxis Precision Medicines, Inc. (PRAX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Praxis Precision Medicines, Inc. (PRAX)

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Praxis: Commercial Launch Could Smash Expectations (Video)

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

Praxis Precision Medicines Q2 Earnings Call Highlights

Stock Picks From Seeking Alpha's July 2026 New Analysts

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Praxis: Commercial Launch Could Smash Expectations (Video)

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

Praxis Precision Medicines Q2 Earnings Call Highlights

Stock Picks From Seeking Alpha's July 2026 New Analysts

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Praxis Precision Medicines, Inc. (PRAX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Praxis Precision Medicines, Inc. (PRAX)

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Praxis: Commercial Launch Could Smash Expectations (Video)

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

Praxis Precision Medicines Q2 Earnings Call Highlights

Stock Picks From Seeking Alpha's July 2026 New Analysts

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Praxis: Commercial Launch Could Smash Expectations (Video)

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

Praxis Precision Medicines Q2 Earnings Call Highlights

Stock Picks From Seeking Alpha's July 2026 New Analysts

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)